Month: July 2026

Seeing blood in the toilet bowl or on toilet paper can be alarming, particularly when it happens without pain. Knowing the top signs bladder cancer may cause helps patients seek assessment early, while recognising that these symptoms can also arise from more common conditions such as urinary infection, stones or prostate enlargement.

Bladder cancer occurs when abnormal cells develop in the lining of the bladder. It is more common in older adults and in men, but it can affect anyone. The most significant warning sign is blood in the urine, even when it appears only once and then disappears.

Top signs of bladder cancer

Blood in the urine

Blood in the urine, known medically as haematuria, is the symptom most commonly associated with bladder cancer. It may be clearly visible, making urine look pink, red, rust-coloured or dark brown. At times, blood is present only in small amounts and is detected during a urine test rather than seen by the patient.

Visible haematuria should always be assessed, even if there is no pain, the bleeding settles quickly, or it occurs after exercise. Bladder cancer bleeding may be intermittent. A normal-looking urine sample on the following day does not rule out a significant cause.

Blood in urine can also result from infection, urinary stones, kidney conditions, prostate problems or some medicines. The cause cannot be determined from appearance alone. A GP can arrange initial testing and referral for specialist urological assessment where appropriate.

New urinary urgency or frequency

Needing to pass urine more often than usual, rushing to the toilet with urgency, or waking more frequently overnight can occur when the bladder lining is irritated. These symptoms are common and often have non-cancerous explanations, including a urinary tract infection or an enlarged prostate.

The concern is greater when urinary changes are new, persist after treatment for an infection, or occur alongside haematuria. Rather than assuming symptoms are simply part of ageing, patients should discuss a meaningful change in their usual urinary pattern with their GP.

Burning or discomfort when passing urine

Stinging, burning or discomfort during urination is more often related to infection than bladder cancer. However, bladder tumours can irritate the bladder and produce similar symptoms, sometimes without bacteria being found in urine testing.

If burning symptoms continue despite treatment, recur repeatedly, or are accompanied by blood in the urine, further investigation is warranted. A urine culture is useful, but a negative culture does not explain persistent symptoms by itself.

Difficulty passing urine or a weak stream

A weak urinary stream, straining to pass urine, intermittency or a feeling that the bladder has not emptied fully can have several causes. In men, prostate enlargement is a frequent explanation. Less commonly, a tumour near the bladder outlet or urethra may contribute to obstruction.

These symptoms need assessment based on the full clinical picture. They are particularly relevant when they have developed recently, are worsening, or occur with visible blood in the urine, recurrent infections or unexplained weight loss.

Pelvic, back or bone pain in later-stage disease

Early bladder cancer often causes no pain. Persistent pelvic discomfort, pain in the lower back or flank, and unexplained bone pain are not typical early warning signs, but may occur when more advanced disease affects surrounding structures or has spread.

Pain has many possible causes, including musculoskeletal conditions and urinary stones. It should not be used as a reason to wait for other symptoms to become severe. Blood in the urine with persistent pain requires timely medical review.

Symptoms that need prompt medical assessment

The presence of haematuria does not mean a person has bladder cancer, but it does require an explanation. This is especially true for adults over 40, people who smoke or have smoked, and those with repeated or unexplained urinary symptoms.

Contact a GP promptly if urine is visibly blood-stained, even once. Urgent assessment is appropriate if bleeding is heavy, blood clots are present, there is difficulty or inability to pass urine, or there is severe pain, fever or marked unwellness. These situations may indicate clot retention, infection or obstruction and should not be managed at home.

It is also reasonable to seek review when a presumed urinary infection does not improve as expected. Repeated courses of antibiotics without a confirmed infection can delay identification of an underlying bladder problem.

Who has a higher risk of bladder cancer?

Smoking is the most important modifiable risk factor for bladder cancer. Chemicals from tobacco are filtered by the kidneys and collect in urine, exposing the bladder lining over time. The risk remains higher after quitting than for someone who has never smoked, although stopping smoking remains beneficial at any age.

Risk can also be increased by older age, previous pelvic radiotherapy, long-term irritation of the bladder, certain workplace chemical exposures and a personal history of bladder cancer. Some occupations have historically involved exposure to dyes, rubber, leather, paint and industrial chemicals. Risk factors help guide clinical judgement, but bladder cancer can occur in people without any recognised risk factor.

How a urologist investigates possible bladder cancer

Assessment usually begins with a detailed history, examination and urine testing. A urine sample may be checked for blood, infection and abnormal cells. Blood tests may assess kidney function, particularly if imaging with contrast is being considered.

For patients with visible haematuria or concerning persistent symptoms, imaging of the urinary tract is commonly arranged. A CT urogram may examine the kidneys, ureters and bladder for stones, masses or other causes of bleeding. The most appropriate imaging test depends on kidney function, allergy history and the individual clinical situation.

Cystoscopy

Cystoscopy is central to assessing the bladder. It involves passing a narrow camera through the urethra to inspect the inside of the bladder directly. It is generally performed as a short procedure and allows the urologist to identify areas that may not be fully characterised on imaging.

If an abnormal area is found, a further procedure may be recommended to remove or biopsy the tissue. This is commonly performed through the urethra, without an external incision. The tissue is examined by a pathologist to confirm whether cancer is present and, if so, determine the tumour type and grade.

Why early diagnosis changes management

Many bladder cancers are diagnosed while confined to the inner lining of the bladder. These cancers can often be treated with endoscopic surgery and careful surveillance, because bladder tumours can recur. More invasive cancers may require a broader treatment plan involving surgery, systemic treatment and, in selected cases, radiotherapy.

The right treatment depends on the pathology result, depth of tumour invasion, number and location of tumours, imaging findings and the patient’s overall health. This is why an accurate diagnosis before treatment decisions are made is essential.

Preparing for an appointment

A useful starting point is to note when symptoms began, whether blood was visible, how often it has occurred and whether there was pain, fever or passage of clots. Bring a list of current medicines, previous urinary infections or stone episodes, smoking history and any relevant workplace exposures.

Patients should not stop prescribed blood-thinning medication without advice. These medicines can make bleeding more noticeable, but they do not remove the need to investigate why blood has appeared in the urine.

Urology Health Adelaide provides specialist assessment for patients with haematuria, persistent urinary symptoms and suspected bladder conditions. A clear diagnosis allows treatment to be directed at the cause, rather than repeatedly treating symptoms alone.

If you notice blood in your urine, do not wait for it to happen again. Arrange a medical assessment, even if the urine has returned to its usual colour and you otherwise feel well.

A urinary catheter can feel unfamiliar when you first return home after surgery, particularly if you are recovering from prostate, bladder, kidney or ureteric surgery. Knowing how to manage a catheter after surgery can reduce discomfort, protect the drainage system and help you recognise when to contact your treating team. Your hospital discharge instructions always take priority, as the type of procedure performed and the reason for the catheter determine how long it should remain in place.

A catheter is a soft tube that drains urine from the bladder into a collection bag. It may be inserted through the urethra or, in some circumstances, through a small opening in the lower abdomen. Most patients go home with a urethral catheter attached to a leg bag during the day and a larger drainage bag overnight. The catheter should drain freely without pulling, kinking or becoming disconnected.

Managing a catheter after surgery at home

The most useful principle is simple: keep the tubing secure, keep the bag below bladder level, and avoid unnecessary handling of the connections. Urine flows by gravity. If the bag sits above your bladder, urine may not drain properly and can flow back towards the bladder.

Before leaving hospital, make sure you understand the equipment supplied, how the leg bag attaches, when to use the overnight bag, and the planned date or process for catheter removal. If anything is unclear, ask before discharge. The nursing team can demonstrate the steps and confirm which supplies you will need at home.

Keep the catheter and tubing secure

A catheter should be supported with the securement device or strap provided by the hospital. This reduces traction on the urethra, which can cause pain, leakage around the catheter and bleeding. Position the tubing so it has a gentle curve rather than a sharp bend.

During the day, a leg bag is usually worn under clothing and secured to the thigh or calf, depending on the system provided. Check that the tubing is not trapped under tight clothing, caught on a chair or pulled when getting in and out of bed. Take particular care when changing clothes, using the toilet or moving around the home.

At night, connect the larger drainage bag as instructed and place it on a clean stand or in a container beside the bed. Do not place it directly on the floor. Ensure the tubing has enough length for you to turn in bed without pulling on the catheter, but not so much that it forms loops or kinks.

Empty the bag regularly

Empty the drainage bag before it becomes heavy or overfull. A leg bag is commonly emptied when it is around half to two-thirds full, and always before leaving home or going to sleep. The overnight bag should be emptied in the morning or earlier if needed.

Wash your hands before and after handling the drainage tap. Hold the outlet over the toilet or a clean measuring container if you have been asked to record urine output. Avoid allowing the outlet to touch the toilet, container or your hands. Close the tap securely once the bag is empty.

Some patients are given a urine-measuring chart after surgery. If this applies to you, record the amount and appearance of urine as directed. Otherwise, routine measurement is usually unnecessary unless your surgeon or hospital team has specifically requested it.

Maintain everyday hygiene

A catheter does not require harsh cleaning products or routine antiseptics. Showering is generally preferable to bathing while a catheter is in place, unless your treating team has given different instructions. Let warm water run over the catheter entry area and wash gently with mild soap and water. Rinse well and pat dry.

Do not pull the catheter while washing. Avoid powders, creams or perfumed products around the catheter unless prescribed. These can irritate the skin and do not prevent infection.

The catheter tube and bag should remain connected unless you have been instructed to change a bag or valve. Each disconnection creates an opportunity for bacteria to enter the system. If a connection accidentally comes apart, wash your hands, avoid touching the open ends and follow the instructions provided by your hospital. If you are unsure how to reconnect it safely, contact the treating team.

Urine appearance, fluids and bowel care

Urine may be lightly blood-stained, pink or tea-coloured for a period after urological surgery. Small clots or fine debris can also occur, especially after surgery involving the prostate or bladder. This can be expected in some circumstances, but the pattern matters. Urine should continue to drain, and bleeding should not become progressively heavier.

Unless you have been placed on a fluid restriction because of another medical condition, drink regularly through the day. Water is usually the best choice. Adequate fluid intake helps maintain urine flow and may reduce the concentration of urine, which can otherwise irritate the bladder. There is no benefit in forcing excessive amounts of fluid beyond what your surgical team has advised.

Constipation can make catheter discomfort worse and may increase straining after surgery. Follow your discharge advice regarding fibre, fluids and any prescribed laxatives. Avoid straining to open your bowels. If you are taking opioid pain relief, constipation is more likely and should be addressed early.

Bladder spasms can occur while a catheter is in place. These may feel like cramping, a sudden urge to pass urine, or urine leaking around the catheter despite the bag continuing to drain. Mild spasms can be common after surgery and often settle. However, new or severe pain, significant leakage or poor drainage should be discussed with your treating team, as a kinked tube or blockage may need attention.

Moving safely with a catheter

Gentle walking is commonly encouraged after surgery, provided it is consistent with your discharge plan. Keep the bag below your bladder when walking and secure it properly before standing. Take your time when rising from bed or a chair, particularly if you are also taking pain medication.

Avoid heavy lifting, strenuous exercise, cycling and activities that may pull on the catheter until your surgeon advises otherwise. The appropriate timing depends on the operation. Recovery after robotic prostate surgery, kidney surgery or bladder surgery may involve different restrictions, even when catheter care principles are similar.

You can usually travel short distances with a catheter, but plan ahead. Empty the bag before leaving, take spare equipment if it has been supplied, and ensure the bag is positioned safely rather than resting on a car seat where tubing may kink. For longer travel, seek advice from your surgical team.

When to seek medical advice

Contact your surgeon, hospital ward or GP promptly if the catheter stops draining and you have lower abdominal discomfort or a feeling of a full bladder. Check first for simple causes such as a kinked tube, a closed tap or a bag positioned above bladder level. Do not attempt to flush, remove or replace the catheter yourself unless you have been specifically trained and instructed to do so.

You should also seek prompt advice for fever, chills, worsening lower abdominal or flank pain, cloudy or foul-smelling urine with new symptoms, increasing redness or discharge around the catheter, or persistent leakage around the tube. These may indicate infection, blockage or another complication requiring assessment.

Heavy bright-red bleeding, large blood clots, sudden severe pain, a catheter that falls out, or inability to pass urine after catheter removal require urgent medical attention. If you are seriously unwell or cannot obtain timely clinical advice, attend an emergency department or call 000.

Catheter removal and the days afterwards

Do not remove the catheter early, even if it feels uncomfortable. After certain operations, the catheter protects a surgical join while tissues heal. Removing it too soon can lead to complications. Removal may occur in hospital, at a clinic appointment or through a planned process explained at discharge.

After removal, it is common to experience mild burning on the first few occasions you pass urine, temporary urgency or frequency, and a small amount of blood in the urine. The expected recovery depends on the procedure. Your surgeon will advise what to monitor and when follow-up is required.

If you have questions about your particular catheter, the safest course is to contact the team that performed your surgery. Clear advice tailored to your operation is more useful than trying to manage a concern alone.

A second stone can feel particularly frustrating. For many patients, the most useful next step is not simply treating the immediate pain, but identifying the reasons for recurrent kidney stones and reducing the chance of another episode. Stone disease is often influenced by several factors at once, including urine chemistry, diet, medications, medical conditions and urinary tract anatomy.

A urological assessment can clarify what type of stone has formed, whether there is an obstruction or infection, and whether further investigation is appropriate. This is particularly relevant after repeated episodes, bilateral stones, a strong family history, or stones occurring at a younger age.

Why kidney stones return

Kidney stones form when minerals and other substances in the urine become concentrated enough to crystallise. Those crystals can grow into stones within the kidney and may later move into the ureter, the tube carrying urine from the kidney to the bladder.

A previous stone does not guarantee another will develop. However, it does indicate that the conditions for stone formation have existed before. Without addressing those conditions, recurrence is common. The cause may be straightforward, such as consistently low fluid intake, or it may involve an underlying metabolic or anatomical issue that requires targeted management.

Common reasons for recurrent kidney stones

Low urine volume

Not drinking enough fluid is one of the most common contributors. When urine volume is low, calcium, oxalate, uric acid and other stone-forming substances become more concentrated. This creates a more favourable environment for crystals to form.

This is not only an issue during hot weather. Long workdays, travel, exercise, illness, overnight dehydration and simply forgetting to drink can all reduce urine output. People who work outdoors or in physically demanding roles may be at particular risk if they lose substantial fluid through sweating.

For many patients, the practical aim is to produce a generous volume of pale urine across the day. The exact fluid target should be individualised, particularly for people with heart, kidney or liver conditions who may have fluid restrictions.

The type of stone has not been identified

Not all stones form for the same reason. Calcium oxalate stones are the most common, but calcium phosphate, uric acid, struvite and cystine stones have different drivers and may require different preventive strategies.

Whenever possible, a passed or removed stone should be analysed. A stone composition result can guide dietary advice, urine testing and medication decisions. For example, advice suitable for a calcium oxalate stone may not be sufficient for recurrent uric acid stones, where urine acidity can be a major factor.

High levels of stone-forming substances in urine

Some patients have urine chemistry that makes recurrence more likely. This may include high urinary calcium, oxalate, uric acid or sodium. Others have low urinary citrate, a naturally occurring substance that helps prevent crystals from joining together.

These abnormalities cannot be reliably identified from symptoms alone. A 24-hour urine collection, alongside blood tests and stone analysis, may be recommended after recurrent stones. It provides a clearer picture of urine volume, mineral excretion, acidity and protective factors such as citrate.

The results matter because prevention should be specific. A blanket instruction to avoid calcium, for instance, is not appropriate for every patient and can sometimes be counterproductive.

Diet, sodium and supplement use

Diet can influence stone risk, although the relationship is more nuanced than simply avoiding particular foods. A high sodium intake can increase calcium loss into the urine. Processed foods, takeaway meals, cured meats, savoury snacks and some sauces can contribute significant sodium without being obviously salty.

Very high intakes of animal protein may raise urinary uric acid and reduce citrate in some people. Large quantities of oxalate-rich foods can also be relevant for patients with calcium oxalate stones, particularly when dietary calcium intake is low.

Normal dietary calcium is usually beneficial because calcium in the gut can bind oxalate before it is absorbed. Restricting calcium without specialist advice may therefore increase oxalate absorption and affect bone health. High-dose vitamin C supplements may also increase urinary oxalate in susceptible patients. Supplements should be reviewed as part of a stone assessment rather than stopped or started without guidance.

Medical conditions affecting metabolism or absorption

Certain medical conditions increase the likelihood of stones. These include gout, hyperparathyroidism, chronic diarrhoea, inflammatory bowel disease and conditions following bowel surgery. Recurrent vomiting, poor absorption of nutrients and significant dietary restriction can also alter urine chemistry.

People with diabetes or metabolic syndrome may be more prone to uric acid stones because their urine can be persistently acidic. Hyperparathyroidism can raise blood and urinary calcium levels, creating a different pathway to recurrent calcium stones.

In these circumstances, treating the stone alone may not address the cause. Coordination between a urologist, general practitioner and, where required, a physician or endocrinologist can be important.

Urinary infection

Some stones are associated with infection. Struvite stones can form in the presence of particular bacteria that alter urine chemistry. These stones may grow quickly and, in some cases, fill much of the kidney collecting system.

Repeated urinary tract infections, cloudy or foul-smelling urine, fevers or persistent stone fragments warrant careful assessment. Infection-related stones usually require complete treatment of the stone burden as well as appropriate antibiotic management. Leaving fragments behind can allow the cycle of infection and stone growth to continue.

Urinary tract blockage or anatomy

An obstruction to urine drainage can promote infection, urinary stasis and stone formation. Examples include narrowing at the junction between the kidney and ureter, ureteric strictures, or residual fragments after previous stone treatment.

Imaging may show whether a stone is causing blockage, whether there are stones in both kidneys, or whether an anatomical issue is contributing. The appropriate scan depends on the situation, but may include ultrasound or CT imaging. For patients with complex or recurrent stones, imaging is essential for planning treatment and follow-up.

Medication-related stone risk

A small number of medicines can contribute to stones directly or by changing urine chemistry. This does not mean a prescribed medicine should be stopped independently. Instead, bring an up-to-date medication and supplement list to the consultation so the potential risks and benefits can be reviewed properly.

Where a medication is contributing, the solution may involve a dose adjustment, an alternative treatment or measures to change urine chemistry. In other cases, medication can be used preventively, such as citrate therapy for low urinary citrate or medicines that reduce urinary calcium in selected patients.

Family history and rare inherited conditions

A family history of stones can increase risk. Most recurrent stone disease is not caused by a single inherited disorder, but genetics may influence the way the body handles calcium, oxalate, uric acid and citrate.

Rare conditions, including cystinuria, can cause recurrent stones from a young age and require long-term specialist management. Repeated stone events in childhood or early adulthood, very frequent recurrence, or a family pattern of severe stone disease should prompt more detailed investigation.

When recurrent stones need specialist assessment

A single small stone that passes may not always require extensive metabolic testing. Recurrent episodes are different. Assessment is generally appropriate when stones return, when there are multiple stones in the kidneys, or when an episode has required hospital treatment or surgery.

A specialist review may involve stone analysis, blood tests, urine testing and imaging. The purpose is to establish the stone burden, rule out obstruction or infection, identify correctable risk factors and choose a prevention plan that is realistic for the patient.

Urgent medical assessment is needed if stone symptoms occur with fever, chills, vomiting that prevents fluid intake, severe uncontrolled pain, reduced urine output or a known single functioning kidney. A blocked and infected kidney can become a serious medical emergency.

Prevention is individual, not one-size-fits-all

The most effective prevention plan is based on the stone type and test results. It may include increasing fluid intake, reducing sodium, adjusting dietary protein, maintaining normal dietary calcium, modifying oxalate intake, treating infection, or using preventive medication. For some patients, monitoring small kidney stones with scheduled imaging is appropriate; for others, intervention is recommended because of stone size, location, symptoms or obstruction risk.

At Urology Health Adelaide, recurrent stone assessment focuses on both treatment of existing stones and the factors that may be driving future episodes. Minimally invasive stone procedures may be considered where intervention is required, with follow-up tailored to stone type, imaging findings and individual risk.

A recurrent kidney stone is not simply bad luck to accept. With the right testing and a prevention plan matched to the cause, many patients can substantially reduce the likelihood of another painful episode.

A clear cystoscopy after bladder cancer treatment is reassuring, but it does not usually mark the end of follow-up. Many patients ask, can bladder cancer come back? The answer is yes, particularly for cancers that began in the bladder lining. However, recurrence is not the same for every person, and a structured surveillance plan gives the best opportunity to identify any new tumour early.

Bladder cancer requires ongoing specialist care because its behaviour depends on the original tumour’s stage, grade, number, size and response to treatment. Your urologist can explain what these findings mean for your individual risk and the tests recommended after treatment.

Can bladder cancer come back after treatment?

Bladder cancer can return after initial treatment. This may be a recurrence in the bladder, a new tumour arising elsewhere in the bladder lining, or, less commonly, cancer detected in the ureters or kidneys. In some cases, cancer that was initially confined to the bladder lining can progress into the bladder muscle or beyond.

The distinction between recurrence and progression matters. A recurrence may be a small, low-grade tumour that can be removed through the urethra. Progression means the cancer has become more invasive or biologically aggressive, which may require more extensive treatment. Regular surveillance is designed to detect either situation before symptoms develop.

Most bladder cancers are categorised as either non-muscle-invasive bladder cancer or muscle-invasive bladder cancer. Non-muscle-invasive tumours are confined to the inner layers of the bladder. They commonly recur, although many remain treatable with further bladder-preserving procedures. Muscle-invasive bladder cancer has entered the bladder muscle and carries a greater risk of spread, requiring discussion of treatments such as bladder removal surgery, systemic therapy and radiotherapy in selected circumstances.

Why recurrence happens

Bladder cancer often develops in a lining exposed to factors that can affect the entire urinary tract. This is sometimes described as a field change: even after one tumour has been completely removed, other areas of the bladder lining may retain the capacity to form a new tumour.

Recurrence risk varies considerably. It is influenced by whether the original tumour was low or high grade, how deeply it extended into the bladder wall, whether there were multiple tumours, how large they were, whether carcinoma in situ was present, and whether a tumour has returned previously. Smoking is also a significant risk factor for developing bladder cancer and may affect future risk. Stopping smoking remains worthwhile at any stage.

A tumour that appears to have been removed completely can still recur because microscopic disease may not be visible at the time of surgery, or because a separate new tumour develops later. This does not necessarily mean treatment has failed. It reflects the known biology of bladder cancer and is why surveillance is a central part of care.

Follow-up testing after bladder cancer treatment

For non-muscle-invasive bladder cancer, cystoscopy is the main follow-up test. A fine flexible telescope is passed through the urethra to inspect the inside of the bladder. It is usually performed in a specialist setting and allows the urologist to look directly for recurrent tumours or abnormal areas of lining.

The timing of cystoscopy depends on risk. The first check is commonly performed around three months after tumour removal. Patients with lower-risk tumours may then need less frequent reviews, while those with high-grade, recurrent or high-risk disease require closer and longer-term surveillance. Some patients need lifelong monitoring.

Urine cytology may be used alongside cystoscopy, especially for high-grade disease. This laboratory test looks for abnormal cells shed into the urine. Imaging of the kidneys and ureters, such as CT urography, may also be recommended at intervals or when there is concern about disease higher in the urinary tract.

Follow-up appointments are also an opportunity to review urinary symptoms, treatment effects and smoking cessation. It is reasonable to ask your urologist for a written surveillance schedule so you know when tests are due and which symptoms should prompt earlier contact.

Treatments that can reduce the chance of recurrence

After transurethral resection of a bladder tumour, known as TURBT, some patients receive medicine directly into the bladder. A single dose of intravesical chemotherapy may be used soon after surgery for suitable lower-risk tumours. It aims to reduce the chance that free tumour cells attach to the bladder lining.

For intermediate- or high-risk non-muscle-invasive cancer, a course of intravesical treatment may be advised. Bacillus Calmette-Guerin, commonly called BCG, stimulates an immune response in the bladder and can reduce recurrence and progression risk in appropriate patients. Intravesical chemotherapy is another option in particular clinical circumstances.

These treatments reduce risk but cannot eliminate it. Their suitability depends on pathology results, previous treatment, bladder health, other medical conditions and the availability of treatment. If high-risk cancer continues or returns despite intravesical treatment, bladder removal surgery may be considered. For suitable patients, minimally invasive or robotic approaches may be discussed as part of specialist surgical planning.

Symptoms to report between appointments

Surveillance tests are more reliable than symptoms alone, as early recurrence may cause no noticeable change. Still, patients should contact their GP or urologist promptly if they develop visible blood in the urine, persistent burning when passing urine, a marked increase in urinary frequency, new urgency, difficulty passing urine, or unexplained flank pain.

These symptoms do not automatically mean cancer has returned. Urinary infection, stones, prostate enlargement and treatment-related bladder irritation can produce similar symptoms. Blood in the urine should nevertheless be assessed, particularly in anyone with a history of bladder cancer. Do not wait for the next scheduled cystoscopy if visible bleeding occurs.

If a tumour returns

A recurrent bladder tumour is assessed according to its size, location, appearance and pathology. Many recurrences are managed with another TURBT, followed by a review of whether intravesical treatment should be added or changed. Repeat resections are sometimes necessary when the first specimen does not provide enough information about the depth of invasion, or when high-grade disease is present.

If testing suggests muscle-invasive disease, the treatment pathway changes. Staging scans and multidisciplinary assessment help determine whether surgery, chemotherapy, radiotherapy or a combined approach is most appropriate. Radical cystectomy, which removes the bladder and creates an alternative way for urine to drain, is major surgery. The decision requires careful discussion of cancer control, general health, recovery and the practical implications of urinary reconstruction.

For patients in Adelaide and regional South Australia, timely access to a urologist experienced in bladder cancer surgery and surveillance can make follow-up more manageable. Urology Health Adelaide provides specialist assessment for bladder tumours, including endoscopic management, intravesical treatment planning and surgical consultation where more complex treatment is required.

Questions worth asking at your review

Your pathology report should guide the conversation. Ask whether your cancer was low, intermediate or high risk; whether it was low or high grade; whether it had entered the bladder muscle; and how often cystoscopy and imaging are recommended. It is also useful to ask what result would change the treatment plan and who to contact if bleeding or other symptoms occur between appointments.

Keep each surveillance appointment, even when you feel well. With bladder cancer, early detection of a recurrence often means more treatment options and a better chance of managing it before it becomes more serious.

Blood in the urine can be alarming, particularly when it occurs without pain or other symptoms. Understanding how bladder tumour is diagnosed can make the assessment process clearer: diagnosis usually involves a combination of urine testing, direct inspection of the bladder with a cystoscope, imaging of the urinary tract, and tissue analysis where needed.

A bladder tumour is an abnormal growth arising from the lining of the bladder. Not every episode of blood in the urine is caused by a tumour. Infection, stones, an enlarged prostate and some kidney conditions can also be responsible. However, visible blood in the urine should be assessed promptly, even if it has happened only once and has settled.

When assessment for a bladder tumour is needed

The most common presenting sign is haematuria, the medical term for blood in the urine. It may be visible, turning urine pink, red or brown, or found only on a urine test. Blood may come and go, so the absence of bleeding on a later day does not rule out a problem.

Some patients have urinary symptoms such as a persistent need to pass urine, burning or discomfort when passing urine, increased frequency, or recurrent urinary tract infections. These symptoms are common and often have non-cancerous causes, but they need careful assessment when they persist or occur with haematuria.

Risk is higher with increasing age and a history of smoking. Occupational exposure to certain industrial chemicals and previous pelvic radiotherapy may also be relevant. Risk factors help guide clinical judgement, but a person can develop a bladder tumour without any recognised risk factor.

Initial assessment and urine tests

Assessment begins with a medical history and examination. A urologist will ask about visible or microscopic blood in the urine, urinary symptoms, past infections or stones, medications including blood-thinning medicines, smoking history, previous cancer treatment, and family history where relevant.

A urine sample is usually tested for blood, infection and other abnormalities. If an infection is identified, it may be treated first, followed by repeat testing to confirm that the blood has resolved. Infection and a bladder tumour can occasionally occur together, so persistent haematuria still requires investigation.

Urine cytology

Urine cytology examines urine under a microscope for abnormal cells shed from the urinary tract lining. It can be particularly helpful for detecting high-grade cancer, where cells tend to look more abnormal. A normal cytology result does not exclude a bladder tumour, especially a small or low-grade tumour, so it is used alongside cystoscopy and imaging rather than as a standalone test.

Other urine-based marker tests may be considered in selected circumstances. Their role depends on the clinical setting and local practice. They do not replace direct examination of the bladder where there is a significant concern.

Cystoscopy: looking directly inside the bladder

Cystoscopy is the key test used to inspect the lining of the bladder and urethra. A slender flexible telescope with a camera is passed through the urethra into the bladder. It is commonly performed in rooms using local anaesthetic gel, although the setting can vary according to the patient and the procedure required.

The urologist can view the urethra, prostate region in men, and the bladder lining. The bladder is assessed for growths, areas of inflammation, stones and other changes. Most flexible cystoscopies take only a short time. Patients may experience temporary burning when passing urine or a small amount of blood afterwards. Drinking extra water for the rest of the day may help, unless fluid intake has been restricted for another medical reason.

Cystoscopy is highly useful because many bladder tumours are visible. However, a lesion may need removal or biopsy before its nature can be confirmed. Flat, high-grade changes in the bladder lining can also be subtle, which is one reason urine cytology and clinical history remain relevant.

Imaging of the kidneys, ureters and bladder

Imaging checks the whole urinary tract, not just the bladder. The kidneys and ureters can also be sources of bleeding, and tumours may arise in these areas less commonly.

A CT urogram is often the preferred scan for patients with haematuria who are suitable for contrast imaging. It provides detailed images of the kidneys, ureters and bladder, and can identify masses, stones, blockage or enlarged lymph nodes. The contrast dye is usually given through a vein. Kidney function, allergy history and other health conditions are reviewed before the scan.

An ultrasound may be used in some situations, including when CT contrast is unsuitable or when a less intensive initial study is appropriate. Ultrasound is useful for assessing the kidneys and can identify some bladder abnormalities, but it does not replace cystoscopy and may not detect small bladder lesions. The choice of scan depends on age, symptoms, kidney function, previous imaging and the level of clinical concern.

Confirming the diagnosis with tumour resection and biopsy

If cystoscopy identifies a suspected bladder tumour, the next step is usually a transurethral resection of bladder tumour, often abbreviated to TURBT. This is both a treatment and a diagnostic procedure.

TURBT is performed in hospital under anaesthetic. A telescope is passed through the urethra, so there is no external incision. The surgeon removes the visible tumour and samples tissue from the underlying bladder wall. The specimen is sent to a pathologist, who examines it under a microscope.

The pathology report confirms whether cancer is present and provides details that determine further care. These include the tumour type, grade and depth of invasion. Most bladder cancers are urothelial carcinomas, arising from the cells that line the urinary tract.

Grade and stage are different

Grade describes how abnormal the cancer cells look under the microscope. Low-grade tumours usually grow more slowly and are less likely to invade. High-grade tumours have a greater risk of recurrence and progression, requiring closer surveillance and sometimes additional treatment.

Stage describes how deeply the tumour has grown. A non-muscle-invasive bladder cancer is limited to the inner lining or connective tissue beneath it. A muscle-invasive bladder cancer has grown into the bladder muscle and requires a different treatment discussion, which may involve major surgery, systemic therapy, radiotherapy, or a combination of treatments depending on the individual situation.

The first resection does not always provide the final answer. Where a tumour is high-grade, large, incompletely removed, or has reached certain layers beneath the lining, a repeat resection may be recommended. This can confirm accurate staging and ensure no residual tumour remains.

What happens after diagnosis

Further investigations are guided by the pathology result. For non-muscle-invasive tumours, treatment may include medication placed directly into the bladder after resection or as a course of intravesical treatment. Ongoing cystoscopic surveillance is central to care because bladder tumours can recur, including after successful initial removal.

For muscle-invasive disease, staging scans are used to assess whether cancer has spread beyond the bladder. Treatment planning is individualised and should consider tumour stage, overall health, kidney function, previous treatment, and the patient’s priorities. Where surgery is appropriate, a specialist urological assessment helps clarify the likely benefits, risks and recovery involved.

When to seek prompt medical advice

Visible blood in urine should not be assumed to be an infection, particularly if there is no pain or if it returns after treatment. Seek timely medical assessment for blood in the urine, recurrent urinary infections, difficulty passing urine, unexplained urinary symptoms, or blood clots in the urine. If urine cannot be passed, severe pain develops, or bleeding is heavy, urgent medical care is required.

A clear diagnosis relies on combining the right tests rather than relying on a single result. Early specialist assessment provides the best opportunity to identify the cause of haematuria, confirm a bladder tumour accurately if present, and plan treatment with confidence.

A bladder cancer diagnosis often raises an immediate question: has the cancer remained within the bladder lining, or has it grown deeper or travelled elsewhere? This guide to bladder cancer staging explains how specialists answer that question and why the result directly affects treatment, surveillance and surgical planning.

Staging can feel technical, particularly when it is discussed soon after a cystoscopy or operation. The terms are not simply labels. They describe where the tumour is located, how deeply it has invaded the bladder wall, whether lymph nodes are involved and whether there is evidence of spread to other organs.

What bladder cancer staging tells your specialist

Bladder cancer staging estimates the extent of disease. In Australia, specialists generally use the TNM system, which brings together three separate findings. T describes the primary tumour in the bladder, N describes nearby lymph nodes and M describes distant spread, known as metastasis.

The stage is considered alongside the tumour grade, the appearance of the cells under the microscope, and the tumour type. A low-grade cancer may be less likely to grow or recur aggressively than a high-grade cancer, but grade and stage are not interchangeable. A tumour can be high grade but still confined to the lining, or lower grade but located in a way that requires careful management.

The most useful initial distinction is between non-muscle-invasive bladder cancer and muscle-invasive bladder cancer. Non-muscle-invasive disease is confined to the lining or the connective tissue immediately beneath it. Muscle-invasive disease has grown into the bladder muscle and generally requires more intensive treatment planning.

How bladder cancer is staged

A staging assessment usually develops over several steps. Blood in the urine, urinary symptoms or an abnormal scan may lead to cystoscopy, where a urologist examines the inside of the bladder with a camera. If a suspicious area is found, the next step is usually a transurethral resection of bladder tumour, often called TURBT.

During a TURBT, the surgeon removes visible tumour tissue through the urethra. The tissue is examined by a pathologist, who identifies the tumour type, grade and depth of invasion. This pathology result is central to accurate staging.

Imaging is also used to assess the urinary tract, lymph nodes and other organs. Depending on the circumstances, this may include a CT scan of the chest, abdomen and pelvis, or another form of cross-sectional imaging. Imaging is particularly relevant when there is concern that the cancer has entered the muscle, involved lymph nodes or spread beyond the bladder.

In some cases, staging remains provisional after the first TURBT. A repeat resection may be recommended for high-grade T1 disease, when the first specimen does not include bladder muscle, or when there is concern that tumour remains. This is not necessarily a sign that the cancer is worse. It is a recognised way to obtain more complete information and remove residual disease before finalising a treatment plan.

The T category: depth of tumour invasion

The bladder wall has several layers. The T category reflects how far the cancer has grown through them.

Ta describes a papillary tumour that is confined to the inner lining and has not invaded deeper tissue. These tumours may look like small fronds or growths during cystoscopy.

Tis, also called carcinoma in situ or CIS, is a flat, high-grade cancer confined to the lining. It can be difficult to see and may not form a distinct lump. Despite being non-muscle-invasive, CIS requires close attention because of its higher-risk behaviour.

T1 means cancer has grown through the lining into the connective tissue beneath it, called the lamina propria, but has not entered the bladder muscle. T1 disease is still classed as non-muscle-invasive, although high-grade T1 tumours can carry a significant risk of progression.

T2 means cancer has invaded the bladder muscle. This is muscle-invasive bladder cancer. It is divided into T2a and T2b depending on which part of the muscle layer is involved, although the practical significance for patients is that treatment needs to address more than the bladder lining.

T3 indicates growth through the muscle into the fatty tissue surrounding the bladder. T4 indicates invasion into nearby structures, such as the prostate, uterus, vagina, pelvic wall or abdominal wall. The exact meaning of T4 depends on the structure involved and is assessed in the context of imaging, pathology and surgical findings.

The N and M categories: lymph nodes and spread

The N category records whether cancer is found in regional lymph nodes, which are small immune glands near the bladder. N0 means no regional lymph node involvement has been identified. Higher N categories indicate involvement of one or more lymph nodes in the pelvis or nearby areas.

The M category records distant metastasis. M0 means there is no evidence of distant spread on the available assessment. M1 means cancer has spread to a distant site, such as a distant lymph node, bone, lung or liver. Further tests may be needed if symptoms, blood tests or imaging suggest possible spread.

A scan can be highly informative, but it does not always identify microscopic cancer cells. Equally, enlarged lymph nodes do not always contain cancer. This is one reason staging is reviewed using all available information rather than relying on a single test.

Bladder cancer stages 0 to IV

The TNM findings are often grouped into numbered stages. Stage 0 includes Ta and Tis disease, where cancer is limited to the inner lining. Stage I usually refers to T1 disease, where the tumour has reached the tissue below the lining but not the muscle.

Stage II describes cancer that has entered the bladder muscle. Stage III generally refers to cancer extending beyond the bladder muscle into surrounding fat or nearby organs, and may include some lymph node involvement. Stage IV usually indicates more extensive local invasion, more significant nodal disease or distant metastasis.

These groupings are helpful, but they do not tell the whole story. Two people with the same broad stage can have different tumour grades, health considerations, kidney function, previous treatments and personal priorities. Their recommended care may therefore differ.

How stage influences treatment planning

For non-muscle-invasive bladder cancer, treatment commonly begins with complete TURBT. Depending on the risk of recurrence or progression, treatment may also include medicine placed directly into the bladder after surgery. This can include intravesical chemotherapy or immunotherapy. Regular cystoscopy is an essential part of care because bladder cancer can recur even after successful removal.

Higher-risk non-muscle-invasive disease, particularly high-grade T1 cancer or CIS, may require repeat resection, intensive intravesical treatment and close surveillance. In selected circumstances, surgery to remove the bladder may be discussed earlier because the risk of progression can outweigh the benefit of continued bladder-preserving treatment.

For muscle-invasive bladder cancer, radical cystectomy with pelvic lymph node removal is a standard treatment option for many suitable patients. This operation removes the bladder and requires urinary diversion, such as an ileal conduit or a surgically constructed internal urine reservoir. Chemotherapy may be advised before surgery for appropriate patients, as it can treat cancer cells beyond the visible bladder tumour.

Bladder-preserving treatment with combined chemotherapy and radiotherapy may be suitable for selected patients. It usually requires careful assessment of tumour features, bladder function, overall health and the ability to attend regular follow-up. It is not the right approach for every muscle-invasive cancer, but it is an important discussion in an individualised treatment plan.

More advanced disease may be managed with systemic treatments, which can include chemotherapy, immunotherapy or other cancer medicines, sometimes alongside radiotherapy for symptom control. Care is commonly coordinated between urology, medical oncology, radiation oncology, pathology and radiology.

Questions worth asking after a staging result

At your consultation, it can help to ask whether the tumour is non-muscle-invasive or muscle-invasive, what the exact T stage and grade are, whether bladder muscle was present in the TURBT specimen, and whether a repeat resection is recommended. You may also ask what imaging has shown, whether lymph nodes are a concern and what the goals of each treatment option are.

Bring a support person if possible and ask for unfamiliar terms to be written down. There is often a substantial amount of information to absorb, and a second discussion after pathology or imaging results is common.

At Urology Health Adelaide, staging results are used to guide a precise, specialist-led pathway rather than a one-size-fits-all decision. The most constructive next step is to focus on the information that is known, clarify what still needs to be assessed and discuss the treatment plan that best fits the biology of the cancer and your circumstances.

A kidney stone can cause sudden, severe pain and may lead to emergency treatment, time away from work and repeat procedures. The best ways to prevent kidney stones are not based on a single restrictive diet. They involve understanding the type of stone you form, improving fluid intake and addressing the dietary or medical factors that apply to your individual risk.

Kidney stones develop when minerals and salts in urine become concentrated and form crystals. Some pass without intervention, while others become lodged in the ureter, the narrow tube between the kidney and bladder. Recurrent stones are common, but a structured prevention plan can substantially reduce the chance of another episode.

1. Drink enough fluid to keep urine dilute

For most people with a history of stones, adequate fluid intake is the most effective starting point. The practical aim is not simply to drink a set number of glasses each day, but to produce at least 2 to 2.5 litres of urine over 24 hours. This often requires around 2.5 to 3 litres of fluid daily, and more in hot weather, during exercise or when working outdoors.

Water is the preferred choice. Spread intake across the day rather than drinking a large amount at once. A glass of water with meals, regular drinks between meals and an extra drink before bed can help maintain a more consistent urine volume overnight.

Urine colour offers a simple guide. Pale straw-coloured urine usually suggests good hydration, while dark yellow urine may indicate that more fluid is needed. This is not exact, particularly if you take vitamins or medicines that alter urine colour, but it is useful for day-to-day monitoring.

In South Australia, heat can increase fluid losses quickly. People who work in physically demanding roles, spend long periods outdoors or exercise regularly should plan hydration rather than relying only on thirst. Thirst can lag behind fluid loss.

2. Do not cut dietary calcium without advice

A common misconception is that calcium stones require a low-calcium diet. In fact, most kidney stones are calcium oxalate stones, and restricting dietary calcium can sometimes increase risk. Calcium in food binds oxalate in the bowel, reducing the amount of oxalate absorbed and later passed into the urine.

For many adults, normal dietary calcium from foods such as milk, yoghurt, cheese or calcium-fortified alternatives is appropriate. The best timing is with meals that contain oxalate. Very low calcium intake may also affect bone health.

Calcium supplements require more individual consideration. In some circumstances they may be appropriate, but their dose and timing should be reviewed with your GP, urologist or dietitian, particularly after a stone episode. Do not stop prescribed treatment without medical advice.

3. Reduce excess salt, especially from processed foods

High sodium intake causes the kidneys to pass more calcium into the urine. This can contribute to calcium-based stone formation and may also worsen blood pressure.

The main source is often not salt added at the table. It is packaged and processed food, including takeaway meals, processed meats, savoury snacks, instant noodles, sauces and some ready-made meals. Reading nutrition labels can be helpful, particularly when comparing similar products.

A lower-salt pattern does not need to be bland. Use herbs, spices, garlic, lemon, pepper and vinegar for flavour, and prepare meals at home more often where practical. If you have high blood pressure, heart disease or kidney impairment, salt advice should be coordinated with your treating doctor.

4. Moderate animal protein rather than eliminating it

Large amounts of animal protein can raise urinary calcium and uric acid while lowering citrate, a natural substance that helps prevent crystal formation. Red meat, processed meat, poultry, seafood and high-protein supplements can all contribute when intake is excessive.

This does not mean everyone with kidney stones must avoid meat or follow a vegetarian diet. Portion size and frequency matter. A balanced eating pattern with vegetables, fruit, wholegrains and suitable protein sources is usually more sustainable than severe restriction.

People who have formed uric acid stones may need more specific dietary and medical management. These stones are strongly influenced by urine acidity, and reducing purine-rich foods alone may not be enough. A urine alkalinising medicine may be required in selected cases.

5. Be selective about high-oxalate foods

Oxalate is a naturally occurring compound found in many foods. For people with calcium oxalate stones and high urinary oxalate, reducing very high-oxalate foods may be useful. Examples can include spinach, beetroot, rhubarb, almonds, other nuts, wheat bran, dark chocolate and large amounts of black tea.

The key is proportion. Many foods containing oxalate are otherwise nutritious, so broad dietary restriction is rarely necessary. Instead, avoid frequent large portions of the highest-oxalate foods and eat calcium-containing foods at the same meal.

High-dose vitamin C supplements can increase urinary oxalate in some people. Discuss regular supplement use with your doctor, especially if you have recurrent calcium oxalate stones. Dietary vitamin C from fruit and vegetables is generally not the issue.

6. Choose drinks with stone prevention in mind

Water should make up most fluid intake. Citrus drinks can be useful for some patients because citrate may reduce stone formation. Lemon or lime added to water is a practical option, provided it does not add large amounts of sugar.

Sugar-sweetened soft drinks should be limited, particularly those containing fructose. Frequent intake may increase stone risk and can contribute to weight gain, diabetes and metabolic health concerns. Cola drinks may also be relevant for some people due to their phosphoric acid content, although the overall dietary pattern matters more than any single drink.

Tea and coffee can still fit within a sensible fluid plan for many people. However, they should not replace water entirely, and strong black tea in large quantities may be unsuitable for someone with high urinary oxalate. Alcohol is not a preventive treatment and can lead to dehydration if it displaces water intake.

7. Obtain a stone analysis and metabolic assessment

The most useful prevention plan is based on evidence, not assumptions. If you pass a stone, collect it if possible and arrange laboratory analysis. The composition may be calcium oxalate, calcium phosphate, uric acid, struvite or cystine, with each type requiring different considerations.

Patients with recurrent stones, multiple stones, a strong family history, stones at a younger age, a solitary kidney, bowel disease or impaired kidney function may benefit from a metabolic assessment. This commonly includes blood tests and one or two 24-hour urine collections.

A 24-hour urine test can identify issues such as low urine volume, high calcium, high oxalate, high uric acid, low citrate or persistently acidic urine. Results guide treatment far more accurately than generic dietary advice. For example, low citrate may be managed differently from high urinary calcium, and a uric acid stone needs a different strategy again.

When medication may help prevent another stone

Diet and fluid measures are the foundation, but they are not always sufficient. Depending on the stone type and urine findings, medication may be recommended. Options can include thiazide-type medicines for high urinary calcium, potassium citrate to increase urinary citrate or alkalinise urine, and allopurinol in selected patients with elevated uric acid.

Medicines should be prescribed and monitored carefully. They are not interchangeable, and they work best alongside adequate fluid intake and targeted dietary changes. Follow-up urine testing may be used to confirm that the treatment is achieving the intended effect.

When to seek specialist assessment

Urgent medical assessment is needed for severe pain with fever or chills, vomiting that prevents fluid intake, reduced urine output, a known single kidney, or suspected obstruction. A blocked infected kidney requires prompt treatment.

Arrange specialist review if stones recur, do not pass, are associated with repeated urinary infections, or if imaging shows stones remaining in the kidney. Modern treatment may involve observation, medical management, shockwave therapy, ureteroscopy or percutaneous stone surgery, depending on stone size, location and anatomy.

Urology Health Adelaide can assess recurrent stone disease, investigate the cause and develop a prevention plan tailored to your results. The aim is not simply to treat the current stone, but to reduce the likelihood that the next one develops.

Small, consistent changes usually matter more than a short period of strict dieting. Keep water within reach, make food adjustments that match your stone type, and seek review when stones recur or symptoms change.

A stone causing severe flank pain, repeated infection or blockage of urine flow needs timely assessment. Understanding how kidney stone surgery works can make the treatment pathway less daunting: the aim is usually to break up or remove the stone, restore drainage from the kidney and reduce the chance of ongoing pain or infection.

Kidney stone surgery is not a single operation. The most suitable procedure depends on the stone’s size, location and density, as well as the anatomy of the urinary tract, kidney function and whether infection or obstruction is present. CT imaging is commonly used to define these details before treatment is planned.

When kidney stones need surgery

Many small stones pass without an operation, particularly when they are located in the lower part of the ureter, the tube between the kidney and bladder. Pain relief, fluid advice and medication to assist stone passage may be appropriate in selected cases.

Surgery is considered when a stone is unlikely to pass, pain remains difficult to control, urine drainage is blocked, infection is present, kidney function is at risk, or stones are recurrent. Larger stones within the kidney may also require active treatment even if they are causing few symptoms, particularly if they are growing or associated with repeated urinary tract infections.

An infected obstructed kidney is an urgent situation. In this setting, the first priority is to drain the urine with a ureteric stent or a nephrostomy tube, together with antibiotics where required. Definitive stone treatment is generally delayed until the infection has settled.

How kidney stone surgery works: three common approaches

The procedure is selected to give the best prospect of clearing the stone with the lowest reasonable risk. More than one treatment may occasionally be needed, especially for large or multiple stones.

Shock wave lithotripsy

Shock wave lithotripsy, often called ESWL, uses focused sound waves generated outside the body to fragment a stone into smaller pieces. There are no surgical cuts. The fragments then pass through the urinary tract over the following days or weeks.

This treatment may suit selected kidney stones and upper ureteric stones, particularly when they are relatively small and not excessively dense. It is less suitable for some larger stones, very hard stones, stones in certain lower kidney locations, and when there is significant obstruction below the stone.

Shock wave treatment is usually performed as a day procedure, sometimes with sedation or anaesthesia depending on the individual circumstances. Passing fragments can cause temporary discomfort, blood in the urine and colic. A stent is not always required, but may be recommended in selected cases.

Ureteroscopy and laser stone treatment

Ureteroscopy is a minimally invasive procedure used for stones in the ureter and many stones within the kidney. While the patient is under general anaesthesia, a fine telescope is passed through the urethra and bladder into the ureter. No incision is made through the skin.

The surgeon identifies the stone directly and uses a laser to break it into dust or smaller fragments. Larger pieces may be removed with specialised instruments. Flexible ureteroscopy allows the surgeon to reach stones in different areas of the kidney through the natural urinary passage.

A temporary ureteric stent is commonly placed at the end of the procedure. This soft internal tube supports drainage while swelling settles and small fragments pass. It may cause urinary frequency, urgency, mild discomfort in the bladder or kidney area, and visible blood in the urine. These effects are usually temporary, but the stent must be removed or exchanged at the planned time.

Percutaneous nephrolithotomy

Percutaneous nephrolithotomy, or PCNL, is generally used for larger kidney stones, including stones that fill a substantial part of the kidney’s collecting system. It is also considered when other approaches are unlikely to provide adequate clearance.

Under general anaesthesia, a small tract is created through the skin of the back into the kidney. A telescope is passed directly into the kidney, allowing the stone to be broken up and removed. A drainage tube or stent may be left temporarily after surgery.

PCNL has a higher level of invasiveness than ureteroscopy or shock wave lithotripsy, but it is often the most effective option for a large stone burden. It usually requires a short hospital stay. The balance between a more involved procedure and the opportunity to clear substantial stones in one treatment is discussed carefully during consultation.

What happens before the procedure

Pre-operative planning starts with imaging and urine testing. A urine infection should be identified and treated before elective stone surgery, as operating in the presence of infection can increase the risk of serious complications. Blood tests may also be required to assess kidney function and general fitness for anaesthesia.

Your surgeon will review medications, particularly blood-thinning medicines, diabetes treatments and supplements. Do not stop prescribed medication without specific instructions from your treating team. Fasting requirements and when to arrive at hospital will be provided before the procedure.

Stone location can change between the original scan and the day of treatment if a stone passes or moves. In some cases, updated imaging is needed to confirm the treatment plan.

Recovery after stone surgery

Recovery varies according to the procedure, stone size and whether a stent or drainage tube is used. Most patients having ureteroscopy or shock wave lithotripsy return home the same day. After PCNL, one or more nights in hospital may be appropriate.

It is common to have mild burning when passing urine, blood-stained urine, urinary frequency and intermittent discomfort for a short period after treatment. Drinking fluids as advised can help maintain urine flow, although excessive fluid intake is not necessary if nausea or significant pain is present. Pain relief should be taken as prescribed.

You should seek urgent medical advice if you develop fever, chills, worsening pain not controlled by medication, persistent vomiting, difficulty passing urine, heavy bleeding or large blood clots. These symptoms can indicate infection, obstruction or another complication requiring prompt assessment.

A follow-up appointment may include imaging to check that the kidney is draining and to assess for residual fragments. If a stent has been inserted, ensure you understand how and when it will be removed. Keeping track of this date is an important part of safe post-operative care.

Risks and realistic expectations

All stone procedures carry some risk. These include bleeding, urinary infection, injury to the ureter or kidney, incomplete stone clearance and the need for a further procedure. Ureteroscopy can occasionally require temporary stenting because swelling prevents safe drainage. PCNL has additional risks associated with creating access to the kidney, including bleeding that may require further treatment, although serious complications are uncommon.

The goal is not simply to treat the stone visible on a scan. For recurrent stone formers, prevention also matters. Analysing retrieved stone material, reviewing diet and fluid intake, and considering blood or urine testing can help identify factors that contribute to new stones. Advice is individualised because the best prevention strategy depends on the stone type and medical history.

At Urology Health Adelaide, stone treatment is planned around the individual patient, with attention to safe drainage, minimally invasive options where appropriate and a clear plan for follow-up. The most helpful next step is a specialist review of your imaging and symptoms, so the procedure recommended reflects the stone you have rather than a one-size-fits-all approach.

A diagnosis of prostate cancer often brings several reports, test results and unfamiliar terms into the same consultation. This guide to prostate cancer staging explains how specialists assess the extent and behaviour of a prostate cancer, and why the result helps shape a treatment recommendation. Staging is not a prediction made from one test alone. It combines clinical examination, blood tests, biopsy findings and, where appropriate, imaging.

For patients, the key point is that a stage provides a common clinical language. It helps your urologist determine whether cancer appears confined to the prostate, whether there is a risk it has extended just beyond it, or whether it has spread further afield. It also informs whether active surveillance, surgery, radiation therapy, hormone treatment or a combined approach may be appropriate.

What prostate cancer staging means

Prostate cancer staging describes how far a cancer has grown or spread at the time it is assessed. Doctors commonly use the TNM system, together with the prostate-specific antigen (PSA) level and the biopsy Grade Group.

TNM stands for tumour, nodes and metastasis. The tumour category describes the local extent of cancer in and around the prostate. The node category records whether nearby lymph nodes appear involved. Metastasis refers to spread to more distant sites, most commonly bones or lymph nodes outside the pelvis.

A patient may hear terms such as localised, locally advanced or metastatic prostate cancer. These are useful broad descriptions, but they do not replace the full assessment. Two men with apparently localised cancer may have different PSA levels and Grade Groups, resulting in very different risk profiles and treatment discussions.

The tests used to determine stage

Staging begins with the information already gathered during diagnosis. A PSA blood test is usually one part of the picture. PSA can rise for reasons other than cancer, including benign prostate enlargement and inflammation, so it is interpreted alongside other findings rather than in isolation.

Your urologist will also consider the digital rectal examination. This examination may identify a firm area, nodule or asymmetry in the prostate. If the prostate feels normal, cancer can still be present, particularly where it is only visible on MRI or detected on biopsy.

Multiparametric MRI provides detailed images of the prostate and nearby tissues. It can help show whether a lesion appears confined within the prostate capsule or may be extending outside it. MRI is valuable, but it cannot confirm every microscopic extension of cancer. Its findings are considered with the biopsy and clinical results.

A prostate biopsy confirms the diagnosis and provides information about how the cancer cells look under a microscope. This includes the Gleason score and Grade Group. The number and location of biopsy samples containing cancer, and the proportion of each sample involved, can also influence the assessment.

For some patients, further imaging is recommended. A PSMA PET-CT scan is increasingly used to assess for cancer beyond the prostate, particularly where PSA or Grade Group suggests a higher risk of spread. CT, bone scan or other imaging may also be used in selected circumstances. The most suitable scan depends on the individual cancer features and local clinical protocols.

Understanding the TNM categories

T: The primary tumour

The T category describes the cancer within the prostate and any local extension. Early prostate cancers may be classified as T1, meaning they were not felt on examination or seen clearly on standard imaging and were identified through PSA testing or biopsy.

T2 cancer appears confined to the prostate. It may involve one part of the gland or both sides, but there is no evidence that it has grown beyond the prostate itself. Many cancers diagnosed at this stage can be managed with curative intent, although the choice between surveillance and active treatment still depends on PSA and Grade Group.

T3 cancer has extended beyond the prostate. This may involve tissue immediately outside the prostate or the seminal vesicles, which sit behind the prostate. It is often described as locally advanced cancer. Treatment can still be curative in suitable patients, but it may require a more complex discussion about surgery, radiation therapy, hormone therapy or combined treatment.

T4 cancer has grown into nearby structures other than the seminal vesicles. This is less common at diagnosis and requires individualised planning through a specialist multidisciplinary team.

N: Regional lymph nodes

The N category refers to lymph nodes in the pelvis, which are a common first site of spread outside the prostate. N0 means there is no evidence of involved regional lymph nodes on the available assessment. N1 means cancer is identified or strongly suspected in regional nodes.

Imaging can detect enlarged or PSMA-avid nodes, but it may not identify very small deposits of cancer. In some cases, lymph node status is confirmed only after surgery and pathological examination of removed nodes. This is one reason a clinical stage before treatment and a pathological stage after surgery can differ.

M: Distant spread

M0 means there is no evidence of distant metastases on staging investigations. M1 means cancer has spread beyond regional pelvic nodes. This may include distant lymph nodes, bone or, less commonly, other organs.

A metastatic diagnosis changes the purpose and sequence of treatment. Care may focus on controlling cancer throughout the body, relieving symptoms where needed and maintaining quality of life. Treatment options continue to develop, and management should be planned with specialist input.

Grade Group and Gleason score

Stage describes where the cancer is. Grade describes how the cancer cells appear and how likely they are to behave aggressively. Both matter.

Pathologists report prostate biopsy results using a Gleason score, which is then translated into a Grade Group from 1 to 5. Grade Group 1 is generally the least aggressive pattern, while Grade Group 5 represents the highest-grade disease. A lower Grade Group does not automatically mean no treatment is needed, and a higher Grade Group does not mean treatment cannot be effective. It does, however, influence the likelihood of cancer extending beyond the prostate or recurring after treatment.

Your report may also use terms such as cribriform pattern or intraductal carcinoma. These microscopic features can affect risk assessment and should be discussed directly with your urologist.

Risk groups: bringing the results together

In practice, doctors often use risk groups alongside TNM staging. These categories combine PSA, Grade Group and clinical stage to classify cancer as low, intermediate or high risk. Intermediate-risk disease may be further separated into favourable and unfavourable groups.

This approach is useful because treatment decisions are rarely based on stage alone. A small, low-grade cancer with a low PSA may be suitable for active surveillance, involving regular PSA testing, MRI and repeat biopsy when indicated. The aim is to avoid or defer treatment where the cancer is unlikely to cause harm while retaining the option of treatment if the cancer changes.

For higher-risk localised or locally advanced cancer, active treatment is more likely to be recommended. Options may include radical prostatectomy, often performed using a robotic-assisted approach where appropriate, radiation therapy, hormone therapy or a combination. The right option depends on cancer characteristics, age, overall health, urinary function, previous treatments and personal priorities.

Clinical stage versus pathological stage

Before treatment, the assigned stage is called the clinical stage. It is based on examination, PSA, biopsy and imaging. It is the best estimate available, but no scan or biopsy can map every microscopic cancer cell.

If the prostate is removed surgically, the pathologist can examine the entire gland and, if removed, any lymph nodes. This produces a pathological stage. It may confirm the clinical assessment or reveal more or less extensive disease than initially suspected.

This distinction should not be viewed as a failure of testing. It reflects the limits of pre-treatment assessment and the fact that prostate cancer can be microscopic beyond what imaging can show. The pathological findings also help determine whether further treatment or closer follow-up is advisable.

Questions worth taking to your consultation

A staging consultation should leave you clear about what is known, what remains uncertain and why a particular management approach is being discussed. Useful questions include: What are my PSA, Grade Group and TNM stage? Does my MRI or PSMA PET-CT show any extension outside the prostate? Is my cancer considered low, intermediate or high risk? What are the realistic benefits and limitations of surveillance, surgery and radiation therapy in my situation?

It is also reasonable to ask whether treatment is intended to cure the cancer, control it over time or manage symptoms. If surgery is being considered, ask about the planned approach, expected hospital stay, recovery and the circumstances in which additional treatment might be recommended after pathology is available.

A stage is a starting point for an informed decision, not a label that defines your future. A specialist urologist can place each result in context and help you proceed with a treatment plan that is clinically sound and suited to your circumstances.

A prostate biopsy is usually recommended after an elevated PSA result, an abnormal prostate examination, or a concerning finding on prostate MRI. To prepare for a prostate biopsy safely, follow the instructions provided by your urologist and hospital carefully. The details can differ according to the biopsy approach, your medical history and the medicines you take.

A biopsy is performed to collect small samples of prostate tissue for laboratory assessment. It can help clarify whether cancer is present and, if so, provide information that guides the next stage of care. Being well prepared reduces avoidable delays and helps manage the small but important risks associated with the procedure.

Understanding your prostate biopsy plan

Before the procedure, your urologist should explain why a biopsy is being considered, how it will be performed and what the results may mean. Modern prostate assessment often incorporates MRI findings, PSA trends, family history, examination findings and overall health. A biopsy decision is therefore not based on a PSA level alone.

Many biopsies are now performed through the skin between the scrotum and anus, known as a transperineal prostate biopsy. This approach may be undertaken under general anaesthetic or sedation, depending on the planned procedure and hospital arrangements. In some circumstances, a transrectal biopsy may be used. The route matters because the preparation, infection-prevention measures and recovery instructions can vary.

Your appointment letter or pre-admission information is the most relevant guide. If any instruction is unclear, contact the urology practice or admitting hospital before the day of surgery rather than making assumptions.

Medicines to discuss before a prostate biopsy

Medication review is one of the most important parts of preparation. Do not stop prescribed medicine independently. Instead, provide your urologist and anaesthetist with a complete list of tablets, injections, supplements and herbal products you use, including doses.

Particular attention is needed for medicines that affect bleeding. These can include warfarin, apixaban, rivaroxaban, dabigatran, clopidogrel, prasugrel, ticagrelor and aspirin. Whether you need to pause one of these medicines depends on why it was prescribed, your individual clotting risk and the type of biopsy planned. Some patients require a specific interruption plan coordinated with their GP, cardiologist or other treating specialist. Others should continue treatment.

Diabetes medicines also require planning, particularly if fasting is required before an anaesthetic. Insulin, injectable diabetes treatments and some tablets may need to be adjusted on the morning of the procedure. Bring your usual medicines with you unless the hospital advises otherwise.

Tell your treating team if you have ever had a reaction to antibiotics, local anaesthetic, general anaesthetic, adhesive dressings or latex. It is also relevant to mention heart, lung, kidney or liver conditions, sleep apnoea, previous serious infection, or an implanted cardiac device.

Infection prevention and bowel preparation

The infection risk after prostate biopsy is generally low, but it is taken seriously. Your urologist may prescribe antibiotics before or around the procedure, depending on the biopsy method and your clinical circumstances. Take them exactly as directed and let the practice know promptly if you cannot take the prescribed antibiotic because of an allergy or side effect.

For a transperineal biopsy, bowel preparation is often minimal or may not be required. For a transrectal biopsy, you may be asked to use an enema beforehand. This is not a universal requirement, so only follow the preparation instructions supplied for your procedure.

Contact the practice before the biopsy if you develop a urinary tract infection, fever, flu-like illness, significant cough, diarrhoea or another acute illness. A biopsy may need to be postponed if there is an active infection or if you are unwell, particularly when an anaesthetic is planned.

Fasting, arrival and transport arrangements

If your biopsy is being performed under general anaesthetic or sedation, you will receive fasting instructions. These usually specify when to stop solid food and when clear fluids must stop. Follow the stated times precisely. Fasting rules are designed to reduce the risk of complications during anaesthesia, and they may differ between hospitals.

Plan to arrive at the hospital or day surgery centre at the advised time, not at the time the procedure itself is scheduled. Admission includes identity checks, consent, nursing assessment and discussion with the anaesthetist where applicable. Bring your referral information, medication list, Medicare and private health fund details if relevant, and any requested imaging or pathology reports.

Arrange for a responsible adult to collect you and stay available after the procedure if you have sedation or a general anaesthetic. You should not drive, operate machinery, make major decisions or sign important documents for at least 24 hours after an anaesthetic. A taxi or rideshare is not usually an appropriate substitute unless accompanied by a responsible adult.

For patients travelling from regional South Australia, it is sensible to consider an overnight stay near the hospital if travel is long or difficult. This is particularly relevant after an afternoon procedure or if you are managing other health conditions.

What to expect on the day

On arrival, you may be asked to provide a urine sample. This can help identify signs of infection before the biopsy proceeds. You will change into a hospital gown and have observations taken, including blood pressure and pulse.

Your urologist will confirm the procedure, answer final questions and ask you to sign consent. This is the appropriate time to raise concerns about bleeding risk, antibiotics, pain relief or the recovery period. The anaesthetist will discuss the planned anaesthetic if one is required.

The biopsy itself is usually relatively brief, although the total hospital stay is longer due to admission, preparation and recovery. Multiple tissue samples are commonly taken, often targeting any area identified on MRI as well as sampling other parts of the prostate. The number of samples does not by itself indicate the likelihood of cancer.

Recovery after the biopsy

Most patients go home on the same day. Mild discomfort in the perineal area, temporary blood in the urine and blood in semen can occur after a prostate biopsy. Blood in semen can persist for several weeks and may appear quite dark or rusty in colour. This is usually expected, but individual recovery varies.

Drink fluids as advised, rest on the day of the procedure and avoid strenuous activity, heavy lifting and cycling for the period recommended by your urologist. Simple pain relief may be appropriate, but use only the medicines your treating team has advised, particularly if you have been asked to avoid anti-inflammatory medication or are restarting blood-thinning treatment.

Temporary difficulty passing urine can occur, particularly in men with pre-existing prostate enlargement or urinary symptoms. Your care team will provide specific instructions about restarting anticoagulant or antiplatelet medicines. Do not restart them early or delay restarting them without medical advice.

Seek urgent medical attention if you develop fever, chills, worsening pain, feel acutely unwell, have heavy or persistent bleeding, cannot pass urine, or notice large clots in the urine. These symptoms may indicate infection, urinary retention or another complication requiring prompt assessment.

Waiting for biopsy results

Biopsy samples are sent to a pathology laboratory for detailed examination. Results are not generally available on the day of the procedure. Your urologist will arrange follow-up to discuss the findings, including whether cancer was identified, the grade of any cancer and whether further imaging, surveillance or treatment should be considered.

A biopsy is an investigation, not a diagnosis in itself. Even when cancer is found, the appropriate management depends on the pathology result, MRI findings, PSA, age, general health and personal priorities. Some prostate cancers require active treatment, while others may be suitable for carefully structured surveillance.

Preparation is not simply about the morning of the procedure. A clear medication plan, reliable transport and an understanding of when to seek help can make the experience safer and less stressful. If you are uncertain about any part of your instructions, asking before your admission is the right next step.